

Roberta Parente

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4400695/publications.pdf>

Version: 2024-02-01

33
papers

894
citations

567281

15
h-index

477307

29
g-index

34
all docs

34
docs citations

34
times ranked

1207
citing authors

#	ARTICLE	IF	CITATIONS
1	The Severe Asthma Network in Italy: Findings and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1462-1468.	3.8	112
2	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	4.6	101
3	Mast cells as effector cells of innate immunity and regulators of adaptive immunity. <i>Immunology Letters</i> , 2016, 178, 10-14.	2.5	84
4	Biomarkers for evaluation of mast cell and basophil activation. <i>Immunological Reviews</i> , 2018, 282, 114-120.	6.0	73
5	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	5.7	47
6	Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. <i>International Archives of Allergy and Immunology</i> , 2018, 175, 126-135.	2.1	45
7	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	3.8	42
8	Anaphylaxis and cardiovascular diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 309-315.	2.3	34
9	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	7.2	34
10	Oral Corticosteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	3.5	30
11	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	7.2	29
12	Evaluation of vaccination safety in children with mastocytosis. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 93-95.	2.6	28
13	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	10.0	26
14	Living with Chronic Spontaneous Urticaria in Italy: A Narrative Medicine Project to Improve the Pathway of Patient Care. <i>Acta Dermato-Venereologica</i> , 2017, 97, 81-85.	1.3	21
15	Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 318-323.	1.0	21
16	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606.	3.5	18
17	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , 2018, 16, 3.	1.8	15
18	Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder. <i>Clinical and Molecular Allergy</i> , 2021, 19, 26.	1.8	15

#	ARTICLE	IF	CITATIONS
19	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	3.5	14
20	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. Journal of Investigative Dermatology, 2021, 141, 1719-1727.	0.7	14
21	Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 208-218.	3.8	13
22	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1705-1712.e4.	3.8	13
23	Vascular endothelial growth factors and angiopoietins as new players in mastocytosis. Clinical and Experimental Medicine, 2021, 21, 415-427.	3.6	12
24	Flow-mediated dilation shows impaired endothelial function in patients with mastocytosis. Journal of Allergy and Clinical Immunology, 2019, 144, 1106-1111.	2.9	9
25	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. Journal of Immunology Research, 2019, 2019, 1-14.	2.2	8
26	Orofacial granulomatosis: Clinical and therapeutic features in an Italian cohort and review of the literature. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2189-2200.	5.7	8
27	Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study. Thrombosis Research, 2022, 209, 69-74.	1.7	8
28	Pitfalls in anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 382-386.	2.3	7
29	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. British Journal of Haematology, 2021, 193, 845-848.	2.5	6
30	Risk Factors and Cofactors for Severe Anaphylaxis. Current Treatment Options in Allergy, 2018, 5, 204-211.	2.2	3
31	Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study. Journal of Autoimmunity, 2022, 129, 102832.	6.5	3
32	Screening for Hereditary Alpha-Trypsinemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms. Blood, 2021, 138, 1500-1500.	1.4	1
33	Urticarial Vasculitis. A Review of the Literature. , 2016, , 321-329.		0